Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs GeneDx Holdings Corp — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.03 (market cap $378.77M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 5.3× JPMorgan Diversified Return International Eqty ETF's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and GeneDx Holdings Corp for 19 Days on average.
| JPIN | WGS | |
|---|---|---|
Market Cap | $378.77M | $2.02B |
Volume | 13,861 | 734,640 |
52-Week High | $77.80 | $167.51 |
52-Week Low | $64.96 | $34.51 |
Typical Hold Time | 120 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $72.875, down 0.09% with bearish technical signals dominating. The ETF shows oversold conditions with RSI readings below 25, while moving averages and oscillators indicate strong selling pressure. Recent analysis highlights JPIN's focus on international value stocks through a smart beta approach.
The ETF faces significant technical headwinds despite oversold conditions. Investors should weigh the bearish momentum against potential value opportunities in international markets, with the upcoming dividend payment in September 2026 providing income consideration.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
